Pipeline· July 2, 2026 · 17 min read
The Anti-Obesity Phase 3 Pipeline: Active Trials and Mechanisms
By Ran Chen#GLP-1#Weight Loss#Clinical Evidence
Topic
Pivotal Trials
Registrational studies, trial design, primary endpoints, comparator choices, and evidence packages behind approvals.
Approvals· July 2, 2026 · 18 min read
Lifyorli (Relacorilant) FDA Approval and Ovarian Cancer Access
By Ran Chen#FDA Approval#Pivotal Trials#Payer Criteria
Pipeline· June 13, 2026 · 15 min read
ClinicalTrials.gov competitor trial landscape: how launch teams map a crowded indication
Pipeline· June 13, 2026 · 12 min read
ClinicalTrials.gov by the numbers: 589K studies and a 58% Phase 3 results gap
Evidence· June 13, 2026 · 11 min read
EULAR 2026 readouts: CD40L lupus win, IL-17 beats IL-23, off-the-shelf cell therapy
By Ran Chen#Immunology#Clinical Evidence#Pivotal Trials
Pipeline· June 12, 2026 · 9 min read
Retatrutide Phase 3: -28.3% body weight, 45% lose ≥30%, new UTI signal at ADA 2026
By Ran Chen#GLP-1#GIP/GLP-1#Clinical Evidence
Pipeline· June 7, 2026 · 9 min read
Cytisinicline smoking cessation PDUFA preview: first new pharmacotherapy in 20 years
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence
Pipeline· June 5, 2026 · 11 min read
Atacicept PDUFA preview: first dual BAFF/APRIL therapy approaches IgA nephropathy decision
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence
Pipeline· June 5, 2026 · 12 min read
Gedatolisib PDUFA preview: pan-PI3K/mTOR inhibitor targets HR+/HER2– breast cancer gap
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence
Pipeline· June 3, 2026 · 9 min read
Cendakimab PDUFA preview: IL-13 inhibitor for eosinophilic esophagitis
By Ran Chen#PDUFA Date#FDA Approval#Immunology